M
Mahdi Mahdi
Researcher at University of Oxford
Publications - 7
Citations - 313
Mahdi Mahdi is an academic researcher from University of Oxford. The author has contributed to research in topics: Budesonide & Population. The author has an hindex of 2, co-authored 5 publications receiving 113 citations. Previous affiliations of Mahdi Mahdi include National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Sanjay Ramakrishnan,Sanjay Ramakrishnan,Sanjay Ramakrishnan,Dan V. Nicolau,Dan V. Nicolau,Dan V. Nicolau,Beverly Langford,Beverly Langford,Mahdi Mahdi,Mahdi Mahdi,Helen Jeffers,Helen Jeffers,Christine Mwasuku,Christine Mwasuku,Karolina Krassowska,Karolina Krassowska,Robin Fox,Ian Binnian,Victoria Glover,Stephen Bright,Christopher C Butler,Jennifer L Cane,Jennifer L Cane,Andreas Halner,Philippa C Matthews,Philippa C Matthews,Louise E. Donnelly,Jodie L. Simpson,Jonathan R. Baker,Nabil T. Fadai,Stefan Peterson,Thomas Bengtsson,Peter J. Barnes,Richard Russell,Richard Russell,Mona Bafadhel,Mona Bafadhel +36 more
TL;DR: In this paper, an open-label, parallel-group, phase 2, randomised controlled trial (Steroids in COVID-19; STOIC) of inhaled budesonide, compared with usual care, in adults within 7 days of the onset of mild COPD symptoms was performed in the community in Oxfordshire, UK.
Journal ArticleDOI
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis
Jonathan R. Baker,Mahdi Mahdi,Dan V. Nicolau,S. Ramakrishnan,Peter J. Barnes,Jodie L. Simpson,Steven P. Cass,Richard Russell,Louise E. Donnelly,Mona Bafadhel +9 more
TL;DR: The nasal mucosal inflammatory response was investigated in patients recruited to the STOIC trial and in a cohort of SARS-CoV-2-negative healthy controls, recruited from a long-term observational data collection study at the University of Oxford.
Posted ContentDOI
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial
Sanjay Ramakrishnan,Sanjay Ramakrishnan,Sanjay Ramakrishnan,Dan V. Nicolau,Dan V. Nicolau,Dan V. Nicolau,Beverly Langford,Beverly Langford,Mahdi Mahdi,Mahdi Mahdi,Helen Jeffers,Helen Jeffers,Christine Mwasuku,Christine Mwasuku,Karolina Krassowska,Karolina Krassowska,Robin Fox,Ian Binnian,Victoria Glover,Stephen Bright,Christopher C Butler,Jennifer L Cane,Jennifer L Cane,Andreas Halner,Philippa C Matthews,Philippa C Matthews,Louise E Donnelly,Jodie L. Simpson,Jonathan R. Baker,Nabil T. Fadai,Stefan Peterson,Thomas Bengtsson,Peter J. Barnes,Richard Russell,Richard Russell,Mona Bafadhel,Mona Bafadhel +36 more
TL;DR: In this article, the authors conducted a randomized, open label trial of inhaled budesonide, compared to usual care, in adults within 7 days of the onset of mild Covid-19 symptoms.
Journal ArticleDOI
Inhaled Budesonide in the Treatment of Early COVID-19 Illness: A Randomised Controlled Trial
Sanjay Ramakrishnan,Dan V. Nicolau,Beverly Langford,Mahdi Mahdi,Helen Jeffers,Christine Mwasuku,Karolina Krassowska,Ian Binnian,Victoria Glover,Stephen Bright,Christopher C Butler,Jennifer L Cane,Andreas Halner,Philippa C Matthews,Philippa C Matthews,Louise E. Donnelly,Jodie L. Simpson,Jonathan R. Baker,Nabil T. Fadai,Stefan Peterson,Thomas Bengtsson,Peter J. Barnes,Richard Russell,Mona Bafadhel +23 more
TL;DR: Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery following early COVID-19 infection.
Journal ArticleDOI
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial
Sanjay Ramakrishnan,Dan V. Nicolau,Beverly Langford,Mahdi Mahdi,Helen Jeffers,Christine Mwasuku,Karolina Krassowska,Robin Fox,Ian Binnian,Victoria Glover,Stephen Bright,Christopher C Butler,Jennifer L Cane,Andreas Halner,Philippa C Matthews,Louise E Donnelly,Jodie L. Simpson,Jonathan R. Baker,Nabil T. Fadai,Stefan Peterson,Thomas Bengtsson,Peter J. Barnes,Richard Russell,Mona Bafadhel +23 more
TL;DR: In this paper, the authors conducted a randomized, open label trial of inhaled budesonide, compared to usual care, in adults within 7 days of the onset of mild Covid-19 symptoms.